Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Kura/Kyowa Kirin’s Komzifti Comes With QTc Safety Advantage
Nov 13 2025
•
By
Alaric DeArment
The FDA approved Kura and Kyowa Kirin's Komzifti for relapsed/refractory NPM1-mutant AML.
(Shutterstock)
More from New Products
More from Scrip